Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_assertion type Assertion NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_head.
- NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_assertion description "[It is also possible that therapies employing dopamine D1/D2 receptor agonists or COMT inhibitors will be beneficial for patients with negative symptoms in schizophrenia and bipolar disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_provenance.
- NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_assertion evidence source_evidence_literature NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_provenance.
- NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_assertion SIO_000772 15952869 NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_provenance.
- NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_assertion wasDerivedFrom befree-2016 NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_provenance.
- NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_assertion wasGeneratedBy ECO_0000203 NP499205.RAWquyGPdV-7j3_wIh7lpIFubCAHwwWA2No76t1_ci-90130_provenance.